GLYCOMIMETICS INC (GLYC) Fundamental Analysis & Valuation

NASDAQ:GLYC • US38000Q1022

Current stock price

0.157 USD
-0.01 (-5.42%)
At close:
0.1507 USD
-0.01 (-4.01%)
After Hours:

This GLYC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GLYC Profitability Analysis

1.1 Basic Checks

  • In the past year GLYC has reported negative net income.
  • In the past year GLYC has reported a negative cash flow from operations.
  • GLYC had negative earnings in each of the past 5 years.
  • In the past 5 years GLYC always reported negative operating cash flow.
GLYC Yearly Net Income VS EBIT VS OCF VS FCFGLYC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -341.52%, GLYC is not doing good in the industry: 94.25% of the companies in the same industry are doing better.
  • GLYC has a Return On Equity of -712.87%. This is amonst the worse of the industry: GLYC underperforms 81.87% of its industry peers.
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROIC N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
GLYC Yearly ROA, ROE, ROICGLYC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • GLYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLYC Yearly Profit, Operating, Gross MarginsGLYC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. GLYC Health Analysis

2.1 Basic Checks

  • GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GLYC remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for GLYC has been increased compared to 5 years ago.
  • There is no outstanding debt for GLYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLYC Yearly Shares OutstandingGLYC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLYC Yearly Total Debt VS Total AssetsGLYC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -70.45, we must say that GLYC is in the distress zone and has some risk of bankruptcy.
  • GLYC's Altman-Z score of -70.45 is on the low side compared to the rest of the industry. GLYC is outperformed by 96.05% of its industry peers.
  • There is no outstanding debt for GLYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -70.45
ROIC/WACCN/A
WACC9.02%
GLYC Yearly LT Debt VS Equity VS FCFGLYC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.92 indicates that GLYC should not have too much problems paying its short term obligations.
  • GLYC's Current ratio of 1.92 is on the low side compared to the rest of the industry. GLYC is outperformed by 77.38% of its industry peers.
  • A Quick Ratio of 1.92 indicates that GLYC should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.92, GLYC is not doing good in the industry: 76.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
GLYC Yearly Current Assets VS Current LiabilitesGLYC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GLYC Growth Analysis

3.1 Past

  • GLYC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.09%, which is quite impressive.
  • GLYC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
  • GLYC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -90.05% yearly.
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.47%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GLYC will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.05% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y-87.54%
EPS Next 3Y-74.09%
EPS Next 5Y14.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLYC Yearly Revenue VS EstimatesGLYC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2020 2021 2022 2023 2029 2030 2031 2032 50M 100M 150M 200M 250M
GLYC Yearly EPS VS EstimatesGLYC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. GLYC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GLYC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLYC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLYC Price Earnings VS Forward Price EarningsGLYC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLYC Per share dataGLYC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • GLYC's earnings are expected to decrease with -74.09% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-87.54%
EPS Next 3Y-74.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GLYC Dividend Analysis

5.1 Amount

  • No dividends for GLYC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GLYC Fundamentals: All Metrics, Ratios and Statistics

GLYCOMIMETICS INC

NASDAQ:GLYC (6/13/2025, 8:04:55 PM)

After market: 0.1507 -0.01 (-4.01%)

0.157

-0.01 (-5.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14
Earnings (Next)08-06
Inst Owners47.7%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner Change0%
Market Cap10.13M
Revenue(TTM)10.00K
Net Income(TTM)-37.88M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-9900%
EPS NY rev (3m)-359.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 1.91
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -70.45
F-Score2
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)26.82%
Cap/Depr(5y)22.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.47%
EPS Next Y-6.84%
EPS Next 2Y-87.54%
EPS Next 3Y-74.09%
EPS Next 5Y14.05%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A

GLYCOMIMETICS INC / GLYC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GLYCOMIMETICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to GLYC.


What is the valuation status for GLYC stock?

ChartMill assigns a valuation rating of 1 / 10 to GLYCOMIMETICS INC (GLYC). This can be considered as Overvalued.


What is the profitability of GLYC stock?

GLYCOMIMETICS INC (GLYC) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GLYCOMIMETICS INC?

The Earnings per Share (EPS) of GLYCOMIMETICS INC (GLYC) is expected to decline by -6.84% in the next year.